Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Allurion Technologies
Digital Health Roundup: Omar Ishrak’s SPAC; AI In Dermatology, IVF, Imaging; Wellness Apps And Trust
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights how Alife Health is using its AI-based platform for IVF to increase chances for successful pregnancies while Barnaby Pickering discusses how AI Medical Technology is using AI to detect melanoma. Reed Miller talks about weight-loss device maker Allurion Technologies’ signed SPAC deal.
Allurion markets the Allurion Program, a unique temporary gastric balloon treatment paired with a digital health platform to support weight loss. Supported by $70m in new money from a merger with Compute Health Acquisition Corporation, the company hopes to submit a PMA to the FDA for system later this year.
Intragastric balloon-maker Allurion is making some major changes in its executive suite to support its plan to expand its market reach.
The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.
- Digital Health
- Consumables, Central Supplies
Surgical Equipment & Devices
- Minimally or Less Invasive
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.